For the treatment of adult patients suffering from Covid-19, pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India. The nasal spray was launched by the pharma company in partnership with SaNOtize. "Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94 per cent in 24 hours and 99 per cent in 48 hours. Nitric Oxide Nasal Spray (NONS) was safe and well-tolerated in COVID-19 patients. Glenmark to market NONS under the brand name FabiSpray," the company said in a statement.